Significant Accounting Policies (Tables)

6 Months Ended

Dec. 31, 2025

Significant Accounting Policies [Abstract]

The following table summarizes the information about the Company’s concentration of customers:

	Customer A			Customer B			Customer C			Customer D			Customer E			Customer F			Customer G
Three Months Ended December 31, 2025
Revenues, customer concentration risk		30	%		22	%		*			10	%		*			12	%		19	%

Three Months Ended December 31, 2024
Revenues, customer concentration risk		34	%		33	%		13	%		*			*			*			*

Six months December 31, 2025
Revenues, customer concentration risk		27	%		29	%		*			11	%		*			9	%		19	%

Six months December 31, 2024
Revenues, customer concentration risk		28	%		25	%		17	%		*			12	%		*			*

As of December 31, 2025
Accounts receivable, customer concentration risk		20	%		*			*			11			*			37	%		32	%

Less than 10%.

Schedule of the Number of Potential Common Shares

The following table sets forth the number of potential Common Shares that have been excluded from diluted net income (loss) per because their effect was anti-dilutive:

	As of December 31,
	2025		2024
Options		196,561		62,416
Warrants		2,588,847		509,580
		2,785,408		571,996

InMed Pharmaceuticals Inc. 10-Q